Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors

In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rilan BAI, Naifei CHEN, Jiuwei CUI
Médium: Artigo
Jazyk:Chinês
Vydáno: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-08-01
Edice:Chinese Journal of Lung Cancer
Témata:
Immune checkpoint inhibitors
Lung neoplasms
EGFR mutation
PD-L1
On-line přístup:http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky